Erschienen in:
09.07.2021 | Original Research
Anterior Segment Optical Coherence Tomography Angiography Assessment of Corneal Vascularisation After Combined Fine-Needle Diathermy with Subconjunctival Ranibizumab: A Pilot Study
verfasst von:
Valencia Hui Xian Foo, Mengyuan Ke, Chelsea Qiu Lin Tan, Leopold Schmetterer, Jodhbir S. Mehta, Marcus Ang
Erschienen in:
Advances in Therapy
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Abstract
Introduction
To describe anterior segment optical coherence tomography angiography (AS-OCTA) imaging to monitor corneal vascularisation (CoNV) and scar reduction after combined fine-needle diathermy (FND) with subconjunctival ranibizumab.
Methods
Prospective clinical study of six eyes from six subjects with corneal scar and CoNV which underwent combined FND with subconjunctival ranibizumab. All eyes were imaged using slit-lamp photography (SLP) and AS-OCTA (Optovue, Inc., Fremont, CA, wavelength: 840 nm) before and after the operation, with two independent masked assessors analysing all images. Main outcome measures were changes in median corneal scar area and vessel density (AS-OCTA) comparing pre- and postoperative imaging up to month 3 and 6.
Results
The mean age of the subjects was 60 ± 23 years, with three males and three females. CoNV and corneal scarring involving the visual axis were present in all eyes, secondary to previous infective keratitis (n = 3), severe blepharokeratoconjunctivitis (n = 2), or chemical injury (n = 1). Follow-up time frame ranged from 2 to 6 months postoperation. There was a reduction in median corneal scar area from 30.2 mm2 (IQR 18.7–38.5) before surgery to 14.8 mm2 (IQR 7.1–19.6) after surgery, with a median reduction of 37.1% (IQR = − 3.1–86.9, p = 0.046). There was also a reduction in median cornea vessel density (AS-OCTA) from 20.8% (IQR 16.1–20.8) before surgery to 17.6% (IQR 14.0–17.6) after surgery, with a median reduction of 15.1% (IQR 13.2–15.1, p < 0.001).
Conclusions
Combined imaging of SLP and AS-OCTA is useful for monitoring treatment response of corneal scarring and CoNV after combined FND with subconjunctival Ranibizumab.